Status:

COMPLETED

Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study

Lead Sponsor:

Beth Israel Deaconess Medical Center

Collaborating Sponsors:

Dartmouth-Hitchcock Medical Center

National Space Biomedical Research Institute

Conditions:

Depression

Eligibility:

All Genders

30-60 years

Phase:

NA

Brief Summary

Use of a computer-based treatment will reduce level of depression.

Detailed Description

Objective Depression can present a significant threat to long-duration space missions, and crews need the ability to recognize it and treat it effectively. We are developing a prototype computer-based...

Eligibility Criteria

Inclusion

  • Criteria for matching to astronaut corps population:
  • Completed 4 or more years of college or university education
  • Age 30-60
  • Has access to a personal computer and regularly uses it (at least twice per week)
  • Clinical criteria:
  • Score of 10 or higher on Hamilton Depression Inventory (which yields equivalent scores to the Hamilton Depression Rating Scale).
  • Has a diagnosis of minor depression consisting of 2 to 4 DSM-IV symptoms of depression, one of which is depressed mood or anhedonia
  • Presence of depressive symptoms for at least 2 weeks but less than 2 years
  • Patient willing to avoid or postpone the use of antidepressant drugs during the treatment portion of the study (6 weeks)

Exclusion

  • Presence of more severe depression or dysthymia within the past 6 months (to rule out persons currently remitting from major depression)
  • Current or past diagnosis of organic mental disorder, schizophrenia, bipolar disorder, or current psychotic symptoms
  • Current suicidal ideation or any history of suicide attempt or self-injurious behavior
  • Presence of comorbid antisocial personality disorder
  • Any current substance abuse/dependence (other than nicotine or caffeine)
  • Suicidal ideation or parasuicidality
  • Current homicidal ideation
  • Recent regimen changes within the past 2 months in prescribed antidepressants, benzodiazepines, or buspirone
  • Currently receiving psychotherapy or mental health counseling
  • Exposure to PST in previous studies
  • Moderate or sever cognitive impairment (Mini Mental State Score \<= 23)
  • Near terminal medical illness (physician estimates \< 6 months to live)

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2009

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT00906581

Start Date

April 1 2009

End Date

September 1 2009

Last Update

April 13 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02120